journal
MENU ▼
Read by QxMD icon Read
search

Pharmaceutical Statistics

journal
https://www.readbyqxmd.com/read/28544622/an-investigation-into-the-two-stage-meta-analytic-copula-modelling-approach-for-evaluating-time-to-event-surrogate-endpoints-which-comprise-of-one-or-more-events-of-interest
#1
Natalie Dimier, Susan Todd
Clinical trials of experimental treatments must be designed with primary endpoints that directly measure clinical benefit for patients. In many disease areas, the recognised gold standard primary endpoint can take many years to mature, leading to challenges in the conduct and quality of clinical studies. There is increasing interest in using shorter-term surrogate endpoints as substitutes for costly long-term clinical trial endpoints; such surrogates need to be selected according to biological plausibility, as well as the ability to reliably predict the unobserved treatment effect on the long-term endpoint...
May 19, 2017: Pharmaceutical Statistics
https://www.readbyqxmd.com/read/28503861/estimates-of-subgroup-treatment-effects-in-overall-nonsignificant-trials-to-what-extent-should-we-believe-in-them
#2
Julien Tanniou, Ingeborg van der Tweel, Steven Teerenstra, Kit C B Roes
In drug development, it sometimes occurs that a new drug does not demonstrate effectiveness for the full study population but appears to be beneficial in a relevant subgroup. In case the subgroup of interest was not part of a confirmatory testing strategy, the inflation of the overall type I error is substantial and therefore such a subgroup analysis finding can only be seen as exploratory at best. To support such exploratory findings, an appropriate replication of the subgroup finding should be undertaken in a new trial...
May 15, 2017: Pharmaceutical Statistics
https://www.readbyqxmd.com/read/28474369/enhancement-of-the-adaptive-signature-design-for-learning-and-confirming-in-a-single-pivotal-trial
#3
Gu Mi
Because of the complexity of cancer biology, often the target pathway is not well understood at the time that phase III trials are initiated. A 2-stage trial design was previously proposed for identifying a subgroup of interest in a learn stage, on the basis of 1 or more baseline biomarkers, and then subsequently confirming it in a confirmation stage. In this article, we discuss some practical aspects of this type of design and describe an enhancement to this approach that can be built into the study randomization to increase the robustness of the evaluation...
May 5, 2017: Pharmaceutical Statistics
https://www.readbyqxmd.com/read/28470952/coping-with-missing-data-in-phase-iii-pivotal-registration-trials-tolvaptan-in-subjects-with-kidney-disease-a-case-study
#4
John Ouyang, Kevin J Carroll, Gary Koch, Junfang Li
Missing data cause challenging issues, particularly in phase III registration trials, as highlighted by the European Medicines Agency (EMA) and the US National Research Council. We explore, as a case study, how the issues from missing data were tackled in a double-blind phase III trial in subjects with autosomal dominant polycystic kidney disease. A total of 1445 subjects were randomized in a 2:1 ratio to receive active treatment (tolvaptan), or placebo. The primary outcome, the rate of change in total kidney volume, favored tolvaptan (P < ...
May 4, 2017: Pharmaceutical Statistics
https://www.readbyqxmd.com/read/28448684/statistical-modeling-for-bayesian-extrapolation-of-adult-clinical-trial-information-in-pediatric-drug-evaluation
#5
Margaret Gamalo-Siebers, Jasmina Savic, Cynthia Basu, Xin Zhao, Mathangi Gopalakrishnan, Aijun Gao, Guochen Song, Simin Baygani, Laura Thompson, H Amy Xia, Karen Price, Ram Tiwari, Bradley P Carlin
Children represent a large underserved population of "therapeutic orphans," as an estimated 80% of children are treated off-label. However, pediatric drug development often faces substantial challenges, including economic, logistical, technical, and ethical barriers, among others. Among many efforts trying to remove these barriers, increased recent attention has been paid to extrapolation; that is, the leveraging of available data from adults or older age groups to draw conclusions for the pediatric population...
April 27, 2017: Pharmaceutical Statistics
https://www.readbyqxmd.com/read/28374497/enabling-robust-assessment-of-qtc-prolongation-in-early-phase-clinical-trials
#6
Devan V Mehrotra, Li Fan, Fang Liu, Kuenhi Tsai
Since the implementation of the International Conference on Harmonization (ICH) E14 guideline in 2005, regulators have required a "thorough QTc" (TQT) study for evaluating the effects of investigational drugs on delayed cardiac repolarization as manifested by a prolonged QTc interval. However, TQT studies have increasingly been viewed unfavorably because of their low cost effectiveness. Several researchers have noted that a robust drug concentration-QTc (conc-QTc) modeling assessment in early phase development should, in most cases, obviate the need for a subsequent TQT study...
May 2017: Pharmaceutical Statistics
https://www.readbyqxmd.com/read/28261972/balanced-covariates-with-response-adaptive-randomization
#7
Benjamin R Saville, Scott M Berry
Response adaptive randomization (RAR) methods for clinical trials are susceptible to imbalance in the distribution of influential covariates across treatment arms. This can make the interpretation of trial results difficult, because observed differences between treatment groups may be a function of the covariates and not necessarily because of the treatments themselves. We propose a method for balancing the distribution of covariate strata across treatment arms within RAR. The method uses odds ratios to modify global RAR probabilities to obtain stratum-specific modified RAR probabilities...
May 2017: Pharmaceutical Statistics
https://www.readbyqxmd.com/read/28251815/a-bayesian-sequential-design-with-binary-outcome
#8
Han Zhu, Qingzhao Yu, Donald E Mercante
Several researchers have proposed solutions to control type I error rate in sequential designs. The use of Bayesian sequential design becomes more common; however, these designs are subject to inflation of the type I error rate. We propose a Bayesian sequential design for binary outcome using an alpha-spending function to control the overall type I error rate. Algorithms are presented for calculating critical values and power for the proposed designs. We also propose a new stopping rule for futility. Sensitivity analysis is implemented for assessing the effects of varying the parameters of the prior distribution and maximum total sample size on critical values...
May 2017: Pharmaceutical Statistics
https://www.readbyqxmd.com/read/28230320/probability-of-success-for-phase-iii-after-exploratory-biomarker-analysis-in-phase-ii
#9
Heiko Götte, Marietta Kirchner, Martin Oliver Sailer
The probability of success or average power describes the potential of a future trial by weighting the power with a probability distribution of the treatment effect. The treatment effect estimate from a previous trial can be used to define such a distribution. During the development of targeted therapies, it is common practice to look for predictive biomarkers. The consequence is that the trial population for phase III is often selected on the basis of the most extreme result from phase II biomarker subgroup analyses...
May 2017: Pharmaceutical Statistics
https://www.readbyqxmd.com/read/27966248/misspecification-of-at-risk-periods-and-distributional-assumptions-in-estimating-copd-exacerbation-rates-the-resultant-bias-in-treatment-effect-estimation
#10
M Law, M J Sweeting, G C Donaldson, J A Wedzicha
In trials comparing the rate of chronic obstructive pulmonary disease exacerbation between treatment arms, the rate is typically calculated on the basis of the whole of each patient's follow-up period. However, the true time a patient is at risk should exclude periods in which an exacerbation episode is occurring, because a patient cannot be at risk of another exacerbation episode until recovered. We used data from two chronic obstructive pulmonary disease randomized controlled trials and compared treatment effect estimates and confidence intervals when using two different definitions of the at-risk period...
May 2017: Pharmaceutical Statistics
https://www.readbyqxmd.com/read/28297160/addressing-potential-prior-data-conflict-when-using-informative-priors-in-proof-of-concept-studies
#11
Timothy Mutsvari, Dominique Tytgat, Rosalind Walley
No abstract text is available yet for this article.
March 2017: Pharmaceutical Statistics
https://www.readbyqxmd.com/read/28206702/statistical-issues-in-first-in-human-studies-on-bia-10-2474-neglected-comparison-of-protocol-against-practice
#12
Sheila M Bird, Rosemary A Bailey, Andrew P Grieve, Stephen Senn
By setting the regulatory-approved protocol for a suite of first-in-human studies on BIA 10-2474 against the subsequent French investigations, we highlight 6 key design and statistical issues, which reinforce recommendations by a Royal Statistical Society Working Party, which were made in the aftermath of cytokine release storm in 6 healthy volunteers in the United Kingdom in 2006. The 6 issues are dose determination, availability of pharmacokinetic results, dosing interval, stopping rules, appraisal by safety committee, and clear algorithm required if combining approvals for single and multiple ascending dose studies...
March 2017: Pharmaceutical Statistics
https://www.readbyqxmd.com/read/28133895/robust-inference-for-group-sequential-trials
#13
Jitendra Ganju, Yunzhi Lin, Kefei Zhou
For ethical reasons, group sequential trials were introduced to allow trials to stop early in the event of extreme results. Endpoints in such trials are usually mortality or irreversible morbidity. For a given endpoint, the norm is to use a single test statistic and to use that same statistic for each analysis. This approach is risky because the test statistic has to be specified before the study is unblinded, and there is loss in power if the assumptions that ensure optimality for each analysis are not met...
March 2017: Pharmaceutical Statistics
https://www.readbyqxmd.com/read/28111916/a-simulation-study-of-methods-for-selecting-subgroup-specific-doses-in-phase-1-trials
#14
Satoshi Morita, Peter F Thall, Kentaro Takeda
Patient heterogeneity may complicate dose-finding in phase 1 clinical trials if the dose-toxicity curves differ between subgroups. Conducting separate trials within subgroups may lead to infeasibly small sample sizes in subgroups having low prevalence. Alternatively,it is not obvious how to conduct a single trial while accounting for heterogeneity. To address this problem,we consider a generalization of the continual reassessment method on the basis of a hierarchical Bayesian dose-toxicity model that borrows strength between subgroups under the assumption that the subgroups are exchangeable...
March 2017: Pharmaceutical Statistics
https://www.readbyqxmd.com/read/28074600/analyzing-multiple-endpoints-in-a-confirmatory-randomized-clinical-trial-an-approach-that-addresses-stratification-missing-values-baseline-imbalance-and-multiplicity-for-strictly-ordinal-outcomes
#15
Hengrui Sun, Atsushi Kawaguchi, Gary Koch
Confirmatory randomized clinical trials with a stratified design may have ordinal response outcomes, ie, either ordered categories or continuous determinations that are not compatible with an interval scale. Also, multiple endpoints are often collected when 1 single endpoint does not represent the overall efficacy of the treatment. In addition, random baseline imbalances and missing values can add another layer of difficulty in the analysis plan. Therefore, the development of an approach that provides a consolidated strategy to all issues collectively is essential...
March 2017: Pharmaceutical Statistics
https://www.readbyqxmd.com/read/27935199/model-averaging-for-treatment-effect-estimation-in-subgroups
#16
Björn Bornkamp, David Ohlssen, Baldur P Magnusson, Heinz Schmidli
In many clinical trials, biological, pharmacological, or clinical information is used to define candidate subgroups of patients that might have a differential treatment effect. Once the trial results are available, interest will focus on subgroups with an increased treatment effect. Estimating a treatment effect for these groups, together with an adequate uncertainty statement is challenging, owing to the resulting "random high" / selection bias. In this paper, we will investigate Bayesian model averaging to address this problem...
March 2017: Pharmaceutical Statistics
https://www.readbyqxmd.com/read/27917593/%C3%AE-markov-model-for-longitudinal-studies-with-incomplete-dichotomous-outcomes
#17
Orestis Efthimiou, Nicky Welton, Myrto Samara, Stefan Leucht, Georgia Salanti
Missing outcome data constitute a serious threat to the validity and precision of inferences from randomized controlled trials. In this paper, we propose the use of a multistate Markov model for the analysis of incomplete individual patient data for a dichotomous outcome reported over a period of time. The model accounts for patients dropping out of the study and also for patients relapsing. The time of each observation is accounted for, and the model allows the estimation of time-dependent relative treatment effects...
March 2017: Pharmaceutical Statistics
https://www.readbyqxmd.com/read/27892650/application-of-bayesian-hierarchical-models-for-phase-i-ii-clinical-trials-in-oncology
#18
Shinjo Yada, Chikuma Hamada
Treatment during cancer clinical trials sometimes involves the combination of multiple drugs. In addition, in recent years there has been a trend toward phase I/II trials in which a phase I and a phase II trial are combined into a single trial to accelerate drug development. Methods for the seamless combination of phases I and II parts are currently under investigation. In the phase II part, adaptive randomization on the basis of patient efficacy outcomes allocates more patients to the dose combinations considered to have higher efficacy...
March 2017: Pharmaceutical Statistics
https://www.readbyqxmd.com/read/27809406/proposed-best-practice-for-projects-that-involve-modelling-and-simulation
#19
Michael O'Kelly, Vladimir Anisimov, Chris Campbell, Sinéad Hamilton
Modelling and simulation has been used in many ways when developing new treatments. To be useful and credible, it is generally agreed that modelling and simulation should be undertaken according to some kind of best practice. A number of authors have suggested elements required for best practice in modelling and simulation. Elements that have been suggested include the pre-specification of goals, assumptions, methods, and outputs. However, a project that involves modelling and simulation could be simple or complex and could be of relatively low or high importance to the project...
March 2017: Pharmaceutical Statistics
https://www.readbyqxmd.com/read/27966259/estimands-new-statistical-principle-or-the-emperor-s-new-clothes
#20
EDITORIAL
Gerd Rosenkranz
No abstract text is available yet for this article.
January 2017: Pharmaceutical Statistics
journal
journal
40610
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"